Compare CRVL & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRVL | IRON |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 1995 | 2020 |
| Metric | CRVL | IRON |
|---|---|---|
| Price | $56.37 | $69.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $103.18 |
| AVG Volume (30 Days) | 187.9K | ★ 346.7K |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | ★ $895,589,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $283.52 |
| P/E Ratio | $36.54 | ★ N/A |
| Revenue Growth | ★ 12.61 | N/A |
| 52 Week Low | $44.83 | $40.00 |
| 52 Week High | $117.22 | $99.50 |
| Indicator | CRVL | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 60.63 |
| Support Level | $51.10 | $57.79 |
| Resistance Level | $71.89 | $69.36 |
| Average True Range (ATR) | 2.04 | 2.64 |
| MACD | 0.29 | 0.94 |
| Stochastic Oscillator | 87.29 | 87.19 |
CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.